Efficacy and safety of MK-5172 and MK-8742 +/- ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: Final results of the C-WORTHY Study (Parts A and B) - Université de Rennes Accéder directement au contenu
Communication Dans Un Congrès Année : 2014

Efficacy and safety of MK-5172 and MK-8742 +/- ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: Final results of the C-WORTHY Study (Parts A and B)

Fichier non déposé

Dates et versions

hal-03252092 , version 1 (07-06-2021)

Identifiants

  • HAL Id : hal-03252092 , version 1

Citer

Eric Lawitz, Edward J. Gane, Brian Pearlman, Edward Tam, Wayne Ghesquiere, et al.. Efficacy and safety of MK-5172 and MK-8742 +/- ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: Final results of the C-WORTHY Study (Parts A and B). 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Nov 2014, Boston, United States. ⟨hal-03252092⟩
12 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More